File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation

TitleA case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation
Authors
Issue Date2000
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2000, v. 96 n. 2, p. 452-458 How to Cite?
AbstractTo compare the clinical and serological outcomes of patients receiving donors' marrow positive or negative for hepatitis B surface antigen (HBsAg), we studied 18 patients of allogeneic hematopoietic cell transplantation receiving HBsAg-positive marrow (group 1) and 18 receiving HBsAg-negative marrow (group 2). The recipients of the 2 groups were matched for hepatitis B virus (HBV) serology, sex, age, underlying hematological diseases, conditioning regimen, and prophylaxis against graft-versus-host diseases. Eight (44.4%) recipients in group 1 and 2 (11.1%) in group 2 suffered from HBV- related hepatitis posttransplant (P = .03). Furthermore, HBV-related hepatic failure was seen in 6 group 1 patients, but in none of the group 2 patients (P = .007). Five of the 9 (55.5%) HBsAg-negative recipients in group 1 became positive after receiving HBsAg-positive marrow. Serum HBV DNA was positive in all 5 donors of these patients, but in none of the donors of recipients who remained HBsAg negative (P = .008). Group 1 patients developing HBV-related hepatitis posttransplant were more likely to have a donor carrying a precore A 1896 and/or core promoter T 1762/A 1764 HBV variant (62.5% versus 0%, P = .007). This study has demonstrated that a high incidence of HBV-related hepatitis was associated with the use of HBsAg- positive marrow for transplant, and a high viral load in the donor appeared to predispose recipients to the development of HBV-related hepatitis posttransplant. Further clinical trials will be necessary to determine the optimal management approach to this problem, including the use of the antiviral agents in the donors and the recipients. (C) 2000 by The American Society of Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/77032
ISSN
2014 Impact Factor: 10.452
2014 SCImago Journal Rankings: 5.246
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLau, GKKen_HK
dc.contributor.authorLie, AKWen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorLee, CKen_HK
dc.contributor.authorHou, Jen_HK
dc.contributor.authorLau, YLen_HK
dc.contributor.authorLim, WLen_HK
dc.contributor.authorLiang, Ren_HK
dc.date.accessioned2010-09-06T07:27:32Z-
dc.date.available2010-09-06T07:27:32Z-
dc.date.issued2000en_HK
dc.identifier.citationBlood, 2000, v. 96 n. 2, p. 452-458en_HK
dc.identifier.issn0006-4971en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77032-
dc.description.abstractTo compare the clinical and serological outcomes of patients receiving donors' marrow positive or negative for hepatitis B surface antigen (HBsAg), we studied 18 patients of allogeneic hematopoietic cell transplantation receiving HBsAg-positive marrow (group 1) and 18 receiving HBsAg-negative marrow (group 2). The recipients of the 2 groups were matched for hepatitis B virus (HBV) serology, sex, age, underlying hematological diseases, conditioning regimen, and prophylaxis against graft-versus-host diseases. Eight (44.4%) recipients in group 1 and 2 (11.1%) in group 2 suffered from HBV- related hepatitis posttransplant (P = .03). Furthermore, HBV-related hepatic failure was seen in 6 group 1 patients, but in none of the group 2 patients (P = .007). Five of the 9 (55.5%) HBsAg-negative recipients in group 1 became positive after receiving HBsAg-positive marrow. Serum HBV DNA was positive in all 5 donors of these patients, but in none of the donors of recipients who remained HBsAg negative (P = .008). Group 1 patients developing HBV-related hepatitis posttransplant were more likely to have a donor carrying a precore A 1896 and/or core promoter T 1762/A 1764 HBV variant (62.5% versus 0%, P = .007). This study has demonstrated that a high incidence of HBV-related hepatitis was associated with the use of HBsAg- positive marrow for transplant, and a high viral load in the donor appeared to predispose recipients to the development of HBV-related hepatitis posttransplant. Further clinical trials will be necessary to determine the optimal management approach to this problem, including the use of the antiviral agents in the donors and the recipients. (C) 2000 by The American Society of Hematology.en_HK
dc.languageengen_HK
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/en_HK
dc.relation.ispartofBlooden_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshBone Marrow Cells - virologyen_HK
dc.subject.meshCase-Control Studiesen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHematopoietic Stem Cell Transplantationen_HK
dc.subject.meshHepatitis B - etiology - mortalityen_HK
dc.subject.meshHepatitis B Antibodies - blooden_HK
dc.subject.meshHepatitis B Surface Antigens - analysisen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshTissue Donorsen_HK
dc.titleA case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0006-4971&volume=96&issue=2&spage=452&epage=458&date=2000&atitle=A+case-controlled+study+on+the+use+of+HBsAg-positive+donors+for+allogeneic+hematopoietic+cell+transplantationen_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityLau, YL=rp00361en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.pmid10887105-
dc.identifier.scopuseid_2-s2.0-0034661838en_HK
dc.identifier.hkuros55820en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034661838&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume96en_HK
dc.identifier.issue2en_HK
dc.identifier.spage452en_HK
dc.identifier.epage458en_HK
dc.identifier.isiWOS:000088234800011-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.scopusauthoridLie, AKW=24284842400en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridLee, CK=36087620900en_HK
dc.identifier.scopusauthoridHou, J=7401966390en_HK
dc.identifier.scopusauthoridLau, YL=7201403380en_HK
dc.identifier.scopusauthoridLim, WL=24492170000en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats